Edward M. Kennedy, Bryan R. Cullen
文献索引:10.1146/annurev-med-051215-031129
全文:HTML全文
The emergence of the CRISPR/Cas system of antiviral adaptive immunity in bacteria as a facile system for gene editing in mammalian cells may well lead to gene editing becoming a novel treatment for a range of human diseases, especially those caused by deleterious germline mutations. Another potential target for gene editing are DNA viruses that cause chronic pathogenic diseases that cannot be cured by using currently available drugs. We review the current state of this field and discuss the potential advantages and problems with using a gene editing approach as a treatment for diseases caused by DNA viruses.
The Type I Interferonopathies
2017-01-18 [10.1146/annurev-med-050715-104506] |
Esophageal Adenocarcinoma: Screening, Surveillance, and Mana...
2017-01-18 [10.1146/annurev-med-050715-104218] |
Management of Rectal Cancer Without Radical Resection
2017-01-18 [10.1146/annurev-med-062915-021419] |
The End of Nihilism: Systemic Therapy of Advanced Non–Small ...
2017-01-18 [10.1146/annurev-med-042915-102442] |
CAR T Cell Therapy for Solid Tumors
2017-01-18 [10.1146/annurev-med-062315-120245] |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved